BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schaaf HS, Garcia-prats AJ, Mckenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Review of Clinical Pharmacology 2018;11:233-44. [DOI: 10.1080/17512433.2018.1421067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Huynh J, Vosu J, Marais BJ, Britton PN. Multidrug-resistant tuberculous meningitis in a returned traveller. J Paediatr Child Health 2019;55:981-4. [PMID: 30746823 DOI: 10.1111/jpc.14387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Matucci T, Galli L, de Martino M, Chiappini E. Treating children with tuberculosis: new weapons for an old enemy. Journal of Chemotherapy 2019;31:227-45. [DOI: 10.1080/1120009x.2019.1598039] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis 2019;6:2049936119864737. [PMID: 31367376 DOI: 10.1177/2049936119864737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Seddon JA, Johnson S, Palmer M, van der Zalm MM, Lopez-Varela E, Hughes J, Schaaf HS. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. Expert Rev Respir Med 2021;15:221-37. [PMID: 32965141 DOI: 10.1080/17476348.2021.1828069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019;200:e93-e142. [PMID: 31729908 DOI: 10.1164/rccm.201909-1874ST] [Cited by in Crossref: 108] [Cited by in F6Publishing: 43] [Article Influence: 54.0] [Reference Citation Analysis]
6 Nataprawira HM, Septiane I, Sudarwati S, Wulandari DA. Two cases of pre-extensively drug resistant tuberculosis in children in Indonesia. Respir Med Case Rep 2021;34:101544. [PMID: 34824970 DOI: 10.1016/j.rmcr.2021.101544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schaaf HS. Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach. Indian J Pediatr 2019;86:717-24. [PMID: 30656560 DOI: 10.1007/s12098-018-02846-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Madzgharashvili T, Salindri AD, Magee MJ, Tukvadze N, Avaliani Z, Blumberg HM, Kempker RR, Lomtadze N. Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs. J Pediatric Infect Dis Soc 2021;10:457-67. [PMID: 33347564 DOI: 10.1093/jpids/piaa139] [Reference Citation Analysis]
9 Huynh J, Thwaites G, Marais BJ, Schaaf HS. Tuberculosis treatment in children: The changing landscape. Paediatr Respir Rev 2020;36:33-43. [PMID: 32241748 DOI: 10.1016/j.prrv.2020.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Seddon JA, Schaaf HS, Marais BJ, McKenna L, Garcia-Prats AJ, Hesseling AC, Hughes J, Howell P, Detjen A, Amanullah F, Singh U, Master I, Perez-Velez CM, Misra N, Becerra MC, Furin JJ. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med 2018;6:662-4. [PMID: 30191832 DOI: 10.1016/S2213-2600(18)30329-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
11 Snow KJ, Cruz AT, Seddon JA, Ferrand RA, Chiang SS, Hughes JA, Kampmann B, Graham SM, Dodd PJ, Houben RM, Denholm JT, Sawyer SM, Kranzer K. Adolescent tuberculosis. Lancet Child Adolesc Health 2020;4:68-79. [PMID: 31753806 DOI: 10.1016/S2352-4642(19)30337-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
12 Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020;92S:S15-25. [PMID: 32032752 DOI: 10.1016/j.ijid.2020.01.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
13 Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, Hesseling AC, Garcia-Prats AJ. Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. Br J Clin Pharmacol 2018. [PMID: 29952141 DOI: 10.1111/bcp.13696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]